Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?

Nature Clinical Practice Oncology volume 4, pages 78–79 (2007)Cite this article

boxed-textvan den Bent MJ et al. (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715–2722

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cairncross JG and Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360–364

    Article  CAS  Google Scholar 

  2. Cairncross G et al. (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24: 2707–2714

    Article  CAS  Google Scholar 

  3. Abrey LE et al.: Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol, in press

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. in the Department of Neurology at Memorial Sloan–Kettering Cancer Center, AB Lassman is an Assistant Attending Neurologist, and LE Abrey is an Associate Attending Neurologist and Director of Clinical Research, New York, NY, USA.,

    Andrew B Lassman & Lauren E Abrey

Authors
  1. Andrew B Lassman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren E Abrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lauren E Abrey.

Ethics declarations

Competing interests

Both authors have declared research support from Schering-Plough and Sigma-Tau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lassman, A., Abrey, L. Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?. Nat Rev Clin Oncol 4, 78–79 (2007). https://doi.org/10.1038/ncponc0690

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0690

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing